PCVXVaxcyte, Inc.

Healthcare
$71.34+125% 1Y
Latest close: a new 52-week highOct 9, 2026what changed →

The financials

Vaxcyte, Inc. by the numbers

The next results filing is expected around Nov 3, 2026, the same week as a year ago.

Vaxcyte, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$303M−$226Mn/a
Net income−$284M−$167Mn/a
Diluted EPS−$1.97−$1.22n/a
On our screens:Most shorted stocks

Biotechnology

Ranks #173 of 196 by RyuScore

Compare peers
SYRE+7.2%
Spyre Therapeutics, Inc.
IMVT+0.69%
Immunovant, Inc.
PTGX+2.7%
Protagonist Therapeutics, Inc.
RYTM+1.3%
Rhythm Pharmaceuticals, Inc.
IBRX+6.0%
ImmunityBio, Inc.
ABVX-1.0%
ABIVAX Société Anonyme